Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
Christel Larbouret(Inserm), D. Azria(Inserm)
Cited by 49
Related Papers
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|431
<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
|Clinical Cancer Research|2007|84
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
|Cancer Letters|2018|57